[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336797-105":59,"doc-detail-336797-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","multiparametric-profiling-of-her2-enriched-extracellular-vesicles-in-breast-cancer-using-single-extracellular-vesicle-nanoscopy","Multiparametric profiling of HER2-enriched extracellular vesicles in breast cancer using Single Extracellular VEsicle Nanoscopy","","Multiparametric characterization of HER2-enriched extracellular vesicles (EVs) enables improved, noninvasive monitoring of HER2-positive breast cancer and tracking of therapy resistance or HER2-status shifts. The SEVEN platform combines affinity isolation of EVs with super-resolution microscopy to quantify individual EV concentration, size, shape, tetraspanin- and HER2-density, molecular cargo content, and heterogeneity. Trastuzumab-resistant cells produce more EVs with altered tetraspanin/HER2 profiles, and plasma analysis identifies a rare, HER2-enriched EV population.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multiparametric-profiling-of-her2-enriched-extracellular-vesicles-in-breast-cancer-using-single-extracellular-vesicle-nanoscopy/336797/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multiparametric-profiling-of-her2-enriched-extracellular-vesicles-in-breast-cancer-using-single-extracellular-vesicle-nanoscopy/336797.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-16","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does SEVEN address in HER2-positive breast cancer management?","Question",{"text":112,"@type":113},"It addresses the need for new, noninvasive strategies to monitor HER2 status changes and therapy resistance frequently, using extracellular vesicles as biomarker candidates.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does SEVEN quantify extracellular vesicles in this study?",{"text":117,"@type":113},"SEVEN combines affinity isolation of EVs with super-resolution microscopy to provide multiparametric characterization at ~8 nm precision and molecular sensitivity.",{"name":119,"@type":110,"acceptedAnswer":120},"What key EV differences were observed for trastuzumab-resistant cells?",{"text":121,"@type":113},"Trastuzumab-resistant cells secreted more EVs, and those EVs showed lower tetraspanin density with higher HER2 density compared with trastuzumab-sensitive cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336797,1790635903,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Jiang et al. Journal of Nanobiotechnology (2024) 22:589 Journal of Nanobiotechnology  \n[https://doi.org/10.1186/s12951-024-02858-x](https://doi.org/10.1186/s12951-024-02858-x)  \nRESEARCH Open Access  \nMultiparametric profiling of HER2-enriched extracellular vesicles in breast cancer using Single Extracellular VEsicle Nanoscopy  \nNan Jiang 1, Andras Saftics 1, Eugenia Romano 1, Ima Ghaeli 1, Cristal Resto2, Vanessa Robles2, Saumya Das3, Kendall Van Keuren-Jensen4, Victoria L. Seewaldt2 and Tijana Jovanovic-Talisman 1*  \nAbstract  \nBackground Patients with HER2-positive breast cancer can significantly benefit from HER2-directed therapy – such as the monoclonal antibody trastuzumab. However, some patients can develop therapy resistance or change HER2 status. Thus, we urgently need new, noninvasive strategies to monitor patients frequently. Extracellular vesicles (EVs) secreted from tumor cells are emerging as potential biomarker candidates. These membrane-delimited nanoparticles harbor molecular signatures of their origin cells; report rapidly on changes to cellular status; and can be frequently sampled from accessible biofluids.  \nResults Using Single Extracellular VEsicle Nanoscopy (SEVEN) platform that combines affinity isolation of EVs with super-resolution microscopy, here we provide multiparametric characterization of EVs with ~ 8 nm precision and molecular sensitivity. We first interrogated cell culture EVs affinity-enriched in tetraspanins CD9, CD63, and CD81; these transmembrane proteins are commonly found on EV membranes. SEVEN robustly provided critical parameters of individual, tetraspanin-enriched EVs: concentration, size, shape, molecular cargo content, and heterogeneity. Trastuzumab-resistant cells (vs. trastuzumab-sensitive) secreted more EVs. Additionally, EVs from trastuzumab-resistant cells had lower tetraspanin density and higher HER2 density. We also evaluated EVs affinity-enriched in HER2; we found that these EVs (vs. tetraspanin-enriched) were larger and more elongated. We further optimized analytical sample processing to assess a rare population of HER2-enriched EVs from patient plasma. In breast cancer patients with elevated HER2 protein expression (vs. controls), HER2-enriched EVs had distinct characteristics including typically increased number of tetraspanin molecules and larger size. Importantly, these EVs were on average 25-fold more abundant compared to no cancer controls.  \nConclusions SEVEN revealed unique characteristics of HER2-enriched EVs in cultured cells and complex biological fluid. In combination with current clinical approaches, this method is well poised to support precise therapeutic decisions.  \n*Correspondence:  \nTijana Jovanovic-Talisman [ttalisman@coh.org](ttalisman@coh.org)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/l](creativecommons.org/l)icenses/by-nc-nd/4.0/.  \nJiang et al. Journal of Nanobiotechnology (2024) 22:589 Page ","cbCainNjkpqbio6C","https://ap.wps.com/l/cbCainNjkpqbio6C","pdf",2404203,16,"English","# Background\n## HER2 status determination in breast cancer\n## HER2-directed therapies and resistance\n# Results\n## SEVEN platform for multiparametric EV profiling\n## EV differences between trastuzumab-resistant and sensitive cells\n## HER2-affinity enrichment and patient plasma analysis\n# Conclusions","[{\"question\":\"What problem does SEVEN address in HER2-positive breast cancer management?\",\"answer\":\"It addresses the need for new, noninvasive strategies to monitor HER2 status changes and therapy resistance frequently, using extracellular vesicles as biomarker candidates.\"},{\"question\":\"How does SEVEN quantify extracellular vesicles in this study?\",\"answer\":\"SEVEN combines affinity isolation of EVs with super-resolution microscopy to provide multiparametric characterization at ~8 nm precision and molecular sensitivity.\"},{\"question\":\"What key EV differences were observed for trastuzumab-resistant cells?\",\"answer\":\"Trastuzumab-resistant cells secreted more EVs, and those EVs showed lower tetraspanin density with higher HER2 density compared with trastuzumab-sensitive cells.\"}]","Multiparametric profiling of HER2-enriched extracellular vesicles in breast cancer using Single Extracellular VEsicle Nanoscopy | PDF",1790016657,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5502247e1d3598de5d53b4b712453039.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cb4ec501f717cae1a50e4883dc2f46d.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/936cc185f3ee3aef49719504b6e61508.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/404ab9b415f1604f57982cf16f12294f.webp",980,1306]